The Phase 3 trial for finerenone (NCT05901831), investigating its use in patients with chronic kidney disease and type 1 diabetes mellitus, reached primary completion on 2025-08-20. This study enrolled 241 participants to assess the drug's efficacy and safety in this specific population.
Background
Finerenone is being investigated as a treatment for chronic kidney disease (CKD) in individuals also living with type 1 diabetes mellitus. CKD involves a progressive decline in kidney function and frequently co-occurs with or results from type 1 diabetes, where insufficient insulin production leads to high blood sugar levels that can harm the kidneys. Finerenone works by blocking specific proteins known as mineralocorticoid receptors, which are believed to contribute to kidney damage when overstimulated.
Trial design
The study, identified as NCT05901831, is a Phase 3 trial. It enrolled 241 participants diagnosed with both chronic kidney disease and type 1 diabetes mellitus. The trial's objective is to evaluate how well finerenone works and its safety profile in this patient group.
What this means
The primary completion of this Phase 3 trial signifies that data collection for the main objectives has concluded. Researchers will now proceed with analyzing the collected data to determine the efficacy and safety profile of finerenone for patients with chronic kidney disease and type 1 diabetes mellitus. The results from this study will be crucial in understanding the potential role of finerenone in managing this complex condition.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05901831, titled "A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes," was updated on 2025-08-20 on clinicaltrials.gov.